Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7945-7952

  Hoshino, Isamu ^a   Matsubara, Hisahiro ^a   Hanari, Naoyuki ^a   Mori, Mikito ^a   Nishimori, Takanori ^a   Yoneyama, Yasuo ^a   Akutsu, Yasunori ^a   Sakata, Haruhito ^a   Matsushita, Kazuyuki ^a   Seki, Naohiko ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BETA ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA DIRECTED DNA POLYMERASE BETA; ERYTHROCYTE BAND 4.1 PROTEIN; FIBRONECTIN; FR 901228; GRANULIN; HEAT SHOCK PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; LAMININ RECEPTOR; MESSENGER RNA; PEROXIREDOXIN; PROSAPOSIN; PROTEIN PRDX1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RIBOPHORIN II; SOMATOMEDIN BINDING PROTEIN; TRANSCRIPTION FACTOR SP1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRDX1 GENE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DEPSIPEPTIDES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEAT-SHOCK PROTEINS; HISTONE DEACETYLASES; HISTONES; HUMANS; IN SITU NICK-END LABELING; INTRONS; MICE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEROXIDASES; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; UP-REGULATION;

EID: 27744476753     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0840     Document Type: Article

References (37)

1. Miller JD, Jain MK, de Gara CJ, Morgan D, Urschel JD. Effect of surgical experience on results of esophagectomy for esophageal carcinoma. J Surg Oncol 1997;65:20-1.
2. Chan A, Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys 1999;45:265-70.
3. Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177-83.
4. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
5. Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromabacterium violaceum No. 968.1. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994;47:301-10.
6. Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T. FR901228, a novel antitumor bicyclic depsi-peptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot (Tokyo) 1994;47:311-4.
7. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-60.
8. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
9. Flaus A, Owen-Hughes T. Mechanisms for ATP-dependent chromatin remodelling: farewell to the tuna-can octamer? Curr Opin Genet Dev 2004;14:165-73.
10. Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev 2001;11:155-61.
11. Jacobson S, Pillus L. Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 1999;9:175-84.
12. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40-8.
13. Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999;94:1401-8.
14. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241:126-33.
15. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000;6:849-66.
16. Kosugi H, Towatari M, Hatano S, et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 1999;13:1316-24.
17. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002;64:1079-90.
18. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activa tes the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997;241:142-50.
19. Nakano K, Mizuno T, Sowa Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997;272:22199-206.
20. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000;19:5712-9.
21. Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A 2004;91:7017-21.
22. Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 1997;11:2456-67.
23. Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 2002;277:43175-84.
24. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000;156:27-35.
25. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003;424:561-5.
26. Mori M, Shimada H, Gunji Y, et al. S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer. Oncol Rep 2004;11:1287-93.
27. Taura K, Yamamoto Y, Nakajima A, et al. Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression. J Gene Med 2004;6:526-36.
28. Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 2004;4:205-18.
29. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998;18:629-43.
30. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003;28:32-40.
31. Prosperi MT, Ferbus D, Karczinski I, Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem 1993;268:11050-6.
32. Prosperi MT, Apiou F, Dutrillaux B, Goubin G. Organization and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene. Genomics 1994;19:236-41.
33. Bai L, Merchant JL. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J Biol Chem 2000;275:30725-33.
34. Doetzlhofer A, Rotheneder H, Lagger G, et al. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999;19:5504-11.
35. Xiao H, Hasegawa T, Isobe K. p300 collaborates with Sp1 and Sp3 in p21 (waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 2000;275:1371-6.
36. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 1999;59:4266-70.
37. Hasegawa T, Xiao H, Isobe K. Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21 (WAF) promoter. Biochem Biophys Res Commun 1999;256:249-54.